GlaxoSmithKline Reports Positive Study Results for Asthma Drug
February 23 2017 - 06:05AM
Dow Jones News
By Tapan Panchal
LONDON--GlaxoSmithKline PLC (GSK.LN) reported positive results
Thursday for a new drug used in the treatment of asthma, a chronic
lung disease that inflames and narrows the airways.
The pharmaceutical company said results from a non-inferiority
lung function study showed that patients with well-controlled
asthma were able to switch to the once-daily Relvar and Ellipta
combination drug, from the twice-daily Seretide and Accuhaler
combination drug without compromising their lung function.
GlaxoSmithKline is jointly developing the asthma drug with
Innoviva Inc. (INVA).
Shares at 1011 GMT were unchanged at 1631 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
February 23, 2017 05:50 ET (10:50 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Mar 2023 to Mar 2024